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Neurobiology of Disease

Transgenic Mouse Model of Tau Pathology in Astrocytes
Leading to Nervous System Degeneration
Mark S. Forman,1,2 Devika Lal,1 Bin Zhang,1 Deepa V. Dabir,1 Eric Swanson,1 Virginia M.-Y. Lee,1,2 and
John Q. Trojanowski1,2
1

Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, and 2Institute on Aging, University of Pennsylvania
School of Medicine, Philadelphia, Pennsylvania 19104

Filamentous tau inclusions in neurons and glia are neuropathological hallmarks of sporadic and familial tauopathies. Because tau gene
mutations are pathogenic for the autosomal dominant tauopathy “frontotemporal dementia and parkinsonism linked to chromosome
17,” tau abnormalities are implicated directly in the onset and/or progression of disease. Although filamentous tau aggregates are
acknowledged to play roles in degenerative mechanisms resulting in neuron loss, the contributions of glial tau pathology to neurodegeneration remain essentially unexplored. To begin to elucidate the role of glial pathology in tauopathies, we generated a transgenic (Tg)
mouse model of astrocytic tau pathology by expressing the human tau protein driven by the glial fibrillary acidic protein (GFAP)
promoter. Whereas endogenous tau was not detected in astrocytes of control mice, in GFAP/tau Tg mice there was robust astrocytic tau
expression that was associated with a redistribution of the GFAP network. Subsequently, there was an age-dependent accumulation of tau
pathology in astrocytes that was Gallyas and variably thioflavine S positive as observed in many tauopathies. The tau pathology in these
Tg mice was abnormally phosphorylated, ubiquitinated, and filamentous, and the emergence of this pathology coincided with accumulation of insoluble tau protein. Furthermore, in regions with robust astrocytic tau pathology, there was mild blood– brain barrier
disruption, induction of low-molecular-weight heat shock proteins, and focal neuron degeneration. Thus, these Tg mice recapitulate key
features of astrocytic pathology observed in human tauopathies and demonstrate functional consequences of this pathology including
neuron degeneration in the absence of neuronal tau inclusions.
Key words: tau protein; astrocytes; neurodegeneration; tauopathy; transgenic mice; blood– brain barrier

Introduction
Filamentous inclusions composed of the microtubule-associated
protein (MAP) tau are defining pathological hallmarks of neurodegenerative diseases referred to as tauopathies, including Pick’s
disease (PiD), progressive supranuclear palsy (PSP), corticobasal
degeneration (CBD), and Alzheimer’s disease (AD) (Lee et al.,
2001). The pathological description of tauopathies other than AD
that manifest tau pathology in the absence of A␤ deposition provided indirect evidence for a causative role of tau in neurodegeneration (Feany and Dickson, 1996). However, the discovery of
mutations in the tau gene in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) provided unequivocal confirmation of the central role of tau abnormalities in
the pathogenesis of tauopathies (Hutton et al., 1998; Poorkaj et
al., 1998; Spillantini et al., 1998).
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Tau is a low-molecular-weight MAP that is abundant in the
CNS, where it is expressed predominantly in axons (Cleveland et
al., 1977). Tau regulates the assembly and stability of microtubules (Weingarten et al., 1975; Cleveland et al., 1977), and this
microtubule-binding function of tau is regulated negatively by
phosphorylation (Drechsel et al., 1992; Biernat et al., 1993; Bramblett et al., 1993). However, tau protein in the filamentous inclusions is abnormally phosphorylated and highly insoluble (Lee et
al., 2001).
In many tauopathies, the tau pathology occurs not only in
neurons but also in astrocytes and oligodendrocytes (Nishimura
et al., 1992; Feany and Dickson, 1995; Komori, 1999). This contrasts with normal CNS expression, wherein tau is present at low
levels in glia (Shin et al., 1991; LoPresti et al., 1995). The distribution of tau pathology in astrocytes does not correlate with the
pattern of neuron loss, suggesting that this pathology reflects an
independent degenerative change rather than a reactive process
(Togo and Dickson, 2002). Therefore, the expression or catabolism of tau protein is altered in glial cells by unknown mechanisms leading to the accumulation of aggregated tau. Whereas the
role of tau pathology in neurons is mostly accepted, the role of the
glial tau pathology in neurodegeneration is completely unknown.
Thus, there are numerous transgenic (Tg) models of tau pathology in neurons, some of which recapitulate many of the features
of tauopathies, including the age-dependent accumulation of fil-
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Table 1. Antibodies
Antibody

Source

Specificity

Reference/source

Ntau
OT12
T14
AT8
AT10
PHF6
PHF41
PHF1
T46
17026
T49
GFAP
RMO24
RMO189
RMO217
1510
Hsp27
␣B-crystallin
Mouse Ig
Albumin
NeuN

Rabbit
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Rabbit
Mouse
Rabbit
Mouse
Mouse
Mouse
Mouse
Goat
Rabbit
Rabbit
Sheep
Mouse

Tau; 1–12
Tau; human specific, exon 2
Tau; human specific, 141–178
Tau; pSer202/pThr205
Tau; pThr212/pSer214
Tau; pThr231
Tau; pThr231
Ptau; pSer396/pSer404
PI tau; 404 – 441
Recombinant tau
PI murine tau
GFAP
NFH; multiphosphorylation repeats
NFM; multiphosphorylation repeats
NFH; multiphosphorylation repeats
Ubiquitin
Hsp27
␣B-crystallin
Mouse Ig
Albumin
NeuN

Dabir et al., 2004
V.M.-Y. Lee, unpublished observation
Kosik et al., 1988
Goedert et al., 1993
Mercken et al., 1992
Hoffmann et al., 1997
Hoffmann et al., 1997
Greenberg and Davies, 1990
Kosik et al., 1988
Ishihara et al., 1999
Mawal-Dewan et al., 1994
DakoCytomation (Carpinteria, CA)
Lee et al., 1988
Lee et al., 1988
Lee et al., 1988
Chemicon (Temecula, CA)
StressGen Biotechnologies (Victoria, British Columbia, Canada)
StressGen Biotechnologies
Jackson ImmunoResearch
Biogenesis (Sandown, NH)
Chemicon

PI, Phosphorylation independent; NFH, neurofilament heavy molecular weight; NFM, neurofilament middle molecular weight.

amentous tau pathology associated with behavioral abnormalities and variable neuron loss (Götz et al., 2004). In contrast, there
are few models systems that address the specific contribution of
glial tau pathology to the pathogenesis of tauopathies (Götz et al.,
2001; Higuchi et al., 2002a; Lin et al.,
2003). However, in all of these systems,
there is tau expression and pathology in
multiple cell lineages, thereby limiting insights into the pathobiology of tau pathology, specifically in astrocytes.
To study the specific contribution of
astrocytic tau pathology to the pathogenesis of tauopathies, we developed a Tg
mouse model of tau pathology restricted
to astrocytes. These Tg mice express the
T34 human tau isoform (Goedert and
Jakes, 1990) under the control of the
astrocyte-specific glial fibrillary acidic
protein (GFAP) promoter, resulting in an
age-dependent accumulation of tau pathology in astrocytes that recapitulates the
astrocytic pathology observed in human
tauopathies. Furthermore, functional consequences of the astrocytic tau pathology
are described.

injected into fertilized C57BL/6 ⫻ C3H (B6C3/F1) mouse embryos and
then implanted into pseudopregnant females. Genomic DNA was isolated from mouse tails of pups with the Puregene DNA Isolation kit
(Gentra Systems, Minneapolis, MN), and potential founders were iden-

Materials and Methods
Generation of GFAP/tau Tg mice. A wild-type
tau cDNA construct containing the T34 human
tau isoform (Goedert and Jakes, 1990) was subcloned into the eukaryotic expression vector
pGfa2-expression vector at the BamHI restriction site that uses the astrocyte-specific GFAP
promoter (Brenner et al., 1994). T34, one of the
most abundant tau isoforms, contains both
exon 2, the first of two alternatively spliced
N-terminal exons, and exon 10, encoding for
the second of four microtubule-binding repeats
that is also alternatively spliced (Goedert and
Jakes, 1990). Linearized constructs were micro-

Figure 1. Expression of human tau in GFAP/tau Tg mice. A–C, Western blot analysis of HS-TBS-soluble proteins (10 g per
lane) extracted from cortex, brainstem (BS), and spinal cord (SC) samples of 2-month-old GFAP/tau Tg and control mice [non-Tg
(NTg)]. Immunoblots were detected with antibodies that detect human tau only (T14; A), murine tau only (T49; B), or both human
and murine tau (T46; C). D, Western blot analysis of native (⫺) and dephosphorylated (⫹) HS-TBS-soluble proteins extracted
from brainstem and probed with T46 that recognizes both mouse and human tau. Arrows in C and D indicate migration of T34
human tau that is specifically expressed in GFAP/tau Tg mice. Molecular weight standards are indicated to the left of each panel.
WT, Wild type; DeP, dephosphorylated.
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sections. Sections were stained with Gallyas silver, thioflavine S, and hematoxylin/eosin stains
using standard protocols. For immunohistochemical analysis, sections were rehydrated and
endogenous peroxide blocked by incubation
with methanol/hydrogen peroxide. Sections
were blocked with 2% fetal bovine serum in 50
mM Tris, pH 7.4, 150 mM NaCl, and incubated
with primary antibody (Table 1) overnight at
4°C. Subsequently, sections were incubated
with
horseradish
peroxidase-conjugated
anti-Ig antibodies (Vector Laboratories, Burlingame, CA) followed by visualization with the
avidin– biotin peroxidase method with 3,3⬘diaminobenzidine as chromagen (Vectastain
ABC kit; Vector Laboratories).
Double-labeling immunofluorescence studies were performed by coincubating sections
with antibodies as indicated (Table 1). After extensive washes, sections were labeled using Alexa Fluor 488- and 594-conjugated secondary
antibodies (Molecular Probes, Eugene, OR),
washed, and coverslipped with Vectashield
4⬘,6⬘-diamidino-2-phenylindole
mounting
medium (Vector Laboratories). The sections
were viewed with an Olympus (Melville, NY)
PX51 microscope equipped with bright-field
and fluorescence light sources. Both brightfield and fluorescent images were obtained
from the same field using a ProGres C14 Jenoptik camera (Laser Optik Systeme, Mainz,
Germany).
Biochemical analysis of tau expression and solubility. The cerebral hemispheres, brainstem
including cerebellum, and spinal cord were dissected from mice after they were anesthetized
lethally in accordance with protocols approved
by the University of Pennsylvania. The tissue
samples were homogenized in 2 ml/g wet tissue
in high-salt Tris-buffered saline (HS-TBS; composed of the following: 50 mM Tris, pH 7.6, 750
mM NaCl, 1 mM EGTA, 0.5 mM MgS04, 20 mM
NaF, 100 M EDTA) supplemented with protease inhibitors (1 mM PMSF and 100 g/ml
each of pepstatin A, leupeptin, soybean trypsin
inhibitor, N-tosyl-L-phenylalanyl chloromethyl
Figure 2. Astrocyte-specific regional tau expression in GFAP/tau Tg mice. A–H, Immunohistochemistry was performed with ketone, and N-tosyl-lysine chloromethyl kethe human tau-specific MAb OT12 on 6-month-old non-Tg (A–D) and GFAP/tau Tg line 4 (E–H ) mice from the CNS regions as tone) and centrifuged at 100,000 ⫻ g for 30 min
indicated. Consistent with the biochemical analysis (Fig. 1), the highest levels of expression were observed consistently in the gray at 4°C. The supernatant was boiled for 5 min
matter of the spinal cord. The inset in E shows morphology of cortical astrocytes at high magnification. Scale bars: (in A) A–C, E–G, and centrifuged at 15,000 ⫻ g for 20 min at 4°C.
200 m; (in D) D, H, 400 m; E, inset, 25 m. I–Q, Spinal cord sections from 6-month-old non-Tg (I–K ) and GFAP/tau Tg, line The resulting supernatant contains the soluble
4 (L–Q) mice were double-labeled with OT12 (green; I, L, O) and GFAP (red; J, M, P). Merged images are depicted in K, N, and Q. tau fraction. To remove myelin and associated
Prominent GFAP staining is observed in astrocytes within the gray matter of Tg mice that is not detected in non-Tg animals. lipids, the insoluble pellets were reextracted
Arrowheads in O indicate the junction of the gray and white matter in the anterior horn of the spinal cord. Scale bars: (in K ) I–N, with 1 M sucrose in HS-TBS and centrifuged at
400 m; (in Q) O–Q, 100 m.
100,000 ⫻ g for 30 min at 4°C. The resulting
pellets were homogenized in radioimmunoprecipitation assay buffer (composed of the followtified by Southern blotting with 32P-labeled T34 cDNA probes. Candiing: 50 mM Tris, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% sodium
date founder lines were backcrossed to non-Tg mice to establish germline
deoxycholate, 1% NP-40, 0.1% SDS supplemented with protease inhibtransmission. Human tau heterozygous mice were bred subsequently to
itors) at 2 ml/g starting tissue and centrifuged as before. The supernatant
homozygosity, and non-Tg littermates were inbred and maintained as
were saved as the detergent-soluble samples, which contained only low
control mice.
levels of tau protein. The detergent-insoluble pellets were extracted with
Histochemical and immunohistochemical analysis. Tg and non-Tg mice
70% formic acid (FA) at 1 ml/g starting wet tissue and disrupted with
were anesthetized lethally by intraperitoneal injection of ketamine hysonication. FA was evaporated in an Automatic Environmental Speeddrochloride (1 mg/10 g) and xylazine (0.1 mg/10 g) and perfused intraVac system (Savant Instruments, Holbrook, NY). The dried pellets were
cardially with 15 ml of PBS followed by 15 ml of 10% neutral buffered
resuspended in SDS sample buffer at a concentration of 1 ml/g starting
formalin or 70% ethanol in isotonic saline in accordance with protocols
wet tissue. Where indicated, tau was dephosphorylated by treatment with
approved by the University of Pennsylvania. The brains and spinal cords
Escherichia coli alkaline phosphatase (Sigma, St. Louis, MO) at 67°C for
were removed and fixed for an additional 24 h, processed by sequential
1 h. For Western blot analysis, nitrocellulose replicas were prepared from
dehydration in ethanol, paraffin-embedded, and cut into 6-m-thick
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7.5% SDS polyacrylamide slab gels containing
either the soluble, detergent-soluble or
-insoluble (FA) tau extracts and probed with a
panel of anti-tau antibodies (Table 1). Primary
antibodies were detected with horseradish
peroxidase-conjugated anti-mouse and antirabbit IgG, respectively (Jackson ImmunoResearch, West Grove, PA). Immunoreactive proteins
were
revealed
using
ECL
chemiluminescence (NEN, Boston, MA).
Quantitative Western blot analysis was performed using either T46 or 17026 followed by 1
Ci/ml I 125-labeled goat anti-mouse or goat
anti-rabbit Ig, respectively (NEN) as secondary
antibodies. The radiolabeled blots were exposed to PhosphorImager plates, and the protein bands were visualized and quantified with
ImageQuant software using endogenous tau
protein expression as an internal standard (Molecular Dynamics, Sunnyvale, CA).
Ultrastructural analysis. Transmission electron microscopy (EM) was performed for the
Tg and control mice at 20 –24 months of age
(n ⫽ 3). These mice were anesthetized deeply
and perfused intracardially with 10 ml of 0.1 M
cacodylate buffer, pH 7.4, containing 0.05%
glutaraldehyde and 0.5% paraformaldehyde,
followed by 50 ml of 0.1 M cacodylate buffer
containing 2% glutaraldehyde and 2% paraformaldehyde. The brain and spinal cord were removed, fixed in 2% glutaraldehyde/2% paraformaldehyde overnight, and postfixed in 2%
osmium tetroxide for 60 min at 4°C. After dehydration with graded alcohol and propylene
oxide, the tissues were embedded in Epon-812
and polymerized at 60°C for 72 h. Sections (65
nm thin) were cut and mounted on 200 mesh
copper grids. The sections were stained with 1%
uranyl acetate in 50% ethanol and bismuth subnitrate and examined with a JEM1010 electron
microscope (Jeol, Peabody, MA) at 80 kV.
Figure 3. Accumulation of tau pathology in aged GFAP/tau Tg mice that resembles astrocytic pathology in human tauopathies.
Preembedding immuno-EM was performed A–F, Immunohistochemical analysis was performed on sections of medulla from 6-month-old (A, D), 12-month-old (B, E), and
on 20- to 24-month-old Tg and control mice 24-month-old (C, F ) GFAP/tau Tg mice, line 4, as indicated with antibodies to recombinant tau (17026; A–C) or tau phosphory(n ⫽ 2 per group). The mice were anesthetized lated at Ser202 and Thr205 (AT8; D–F ). There is an age-dependent accumulation of phosphorylated tau epitopes detected in
deeply and perfused intracardially with 10 ml of GFAP/tau Tg mice. G–L, High-power photomicrographs of astrocytic pathology of Tg mice (G–I ) and human tauopathies (J–L).
0.05% glutaraldehyde, 0.5% paraformaldehyde The astrocytic pathology in the Tg mice resembles the tufted astrocytes (G, J ), astrocytic plaques (H, K ), and thread pathology (I,
in 0.1 M cacodylate buffer, pH 7.4, followed by L) observed in tauopathies such as PSP and CBD. Scale bars: (in A) A–F, 200 m; (in G) G, H, J, K, 40 m; (in I ) I, L, 80 m.
50 ml of 0.2% glutaraldehyde, 2% paraformaldehyde in 0.1 M cacodylate buffer. The brains
dehydrated with graded series of ethanols, and embedded in Eponand spinal cords were removed and postfixed with 4% paraformaldeAraldite resin at 60°C for 48 h. Ultrathin sections of these blocks were cut
hyde, 0.2% glutaraldehyde, 0.2% picric acid in 0.1 M cacodylate buffer
and mounted on 100 mesh EM grids and examined using a JEM1010
overnight. Representative regions from the brainstem and spinal cord
electron microscope at 80 kV.
were dissected and cut into 50-m-thick vibratome sections. Sections
were quenched in 0.1% sodium borohydride in TBS for 10 min followed
Results
by 20% ethanol for 10 min. Nonspecific staining was blocked with 5%
Generation of Tg mice that express human tau specifically
donor horse serum in PBS with 0.1% cold-water fish skin gelatin and 1%
chicken egg albumin for 60 min, and sections were incubated subsein astrocytes
quently with primary antibody in 0.1% bovine serum albumin/PBS overTwo founder lines (lines 4 and 7) of GFAP/tau Tg mice were
night at 4°C. Sections were washed and incubated with biotinylated secobtained that expressed the human tau gene driven by the GFAP
ondary antibodies for 2 h at room temperature followed by visualization
promoter stably with germline transmission, and both lines were
with diaminobenzidine and silver-gold intensification using silver
bred to homozygosity (Fig. 1). Regional tau protein expression
methenamine developer containing 3% methenamine, 5% silver nitrate,
from cortex, brainstem, and spinal cord was determined by imand 1% sodium tetraborate at 60°C for 10 min as described previously
munoblot analysis of the soluble protein extract from 2-month(Ishihara et al., 2001). The reaction was stopped with 2% sodium acetate
old mice. In both line 4 and line 7, tau expression levels was
and then stabilized in 3% sodium thiosulfate for 5 min. Gold toning was
region dependent, with the highest levels consistently observed in
performed by incubating the sections in 0.1% gold chloride for 5 min,
the spinal cord (Fig. 1 A). The expression of human tau protein
followed by stabilizing with 3% sodium thiosulfate for 5 min and overdid not affect the expression of endogenous mouse tau (Fig. 1 B),
night fixation with 2% glutaraldehyde in PBS buffer. Sections with positive staining were postfixed in 0.5% osmium tetroxide for 20 min at 4°C,
and the relative overexpression of human tau protein versus murine
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Tg mice, predominantly in areas of gray
matter (Fig. 2 E–H ). High magnification
revealed tau-positive cells with morphology of protoplasmic astrocytes (Fig. 2 E,
inset). Furthermore, consistent with the
biochemistry data above (Fig. 1), tau staining was more robust in spinal cord relative
to cerebral cortex, subcortical nuclei, and
brainstem regions. In contrast, in non-Tg
mice, there was no immunoreactivity with
human tau-specific antibodies (Fig. 2 A–
D), whereas antibodies that detect human
or murine tau revealed diffuse weak neuropil immunoreactivity consistent with
axonal staining of endogenous mouse tau
(data not shown). To confirm the
astrocyte-specific tau expression, twocolor immunofluorescent staining was
performed with antibodies specific for tau
and GFAP (Fig. 2). In non-Tg mice, there
was no detectable tau immmunostaining
using a human-specific anti-tau antibody
and GFAP staining preferentially in white
matter (Fig. 2 I–K ). In contrast, human
tau protein colocalized in GFAP-positive
astrocytes, predominantly within gray
matter in the GFAP/tau Tg mice (Fig. 2 L–
Q). These astrocytes resemble reactive astrocytes observed in many pathological
conditions of the CNS. Thus, the expression of tau protein in astrocytes leads to
the altered expression of GFAP, a change
Figure 4. Characterization of tau pathology in GFAP/tau Tg mice. A–E, Immunohistochemical analysis was performed on that was observed at all ages analyzed from
sections of pons (A, B) and thalamus (C–E) from 22-month-old GFAP/tau Tg mice, line 4 with a panel of antibodies to distinct 1 to 24 months of age (data not shown),
phosphorylated tau epitopes (A–D) and ubiquitin, as indicated. Ubiquitin (E) is detected only in a subset of tau pathologies. F–I, although this did not correspond to inGallyas silver impregnation (F ) and thioflavine S (ThioS) (G–I ) staining of astrocytic tau pathology in brainstem of 22-month-old creased total GFAP by Western blot analGFAP/tau Tg mice. There is robust Gallyas-positive tau pathology in both astrocytic processes and cell soma. The thioflavine S stain
ysis (data not shown). This change in
detects only a subset of the pathology observed with antibodies to tau phosphoepitopes or Gallyas stains. Scale bars: (in A) A–G,
GFAP staining may reflect a redistribution
80 m; (in I ) H, I, 25 m.
of the intermediate filament network similar to that described with the overexprestau is depicted in Figure 1, C and D. Quantitative Western blot analsion of tau protein in primary rat astrocyte cultures (Yoshiyama
ysis indicated an increase of ⬃25, 50, and 100% of total tau protein
et al., 2003).
expression in cerebral cortex, brainstem, and spinal cord, respectively, relative to endogenous mouse tau. The relative overexpression
Tau pathologies in GFAP/tau Tg mice resembles astrocytic
of human tau compared with endogenous mouse tau levels was conpathology in human tauopathies
sistently highest in the spinal cord of both lines as a result of the lower
Human tauopathies such as PSP and CBD are characterized by
levels of endogenous tau in the spinal cord and the enigmatic inthe accumulation of abnormally phosphorylated and biochemicreased human tau expression in the spinal cord driven by the GFAP
cally insoluble tau protein in astrocytes, oligodendrocytes, and
promoter. Dephosphorylation of the extracted tau protein with alneurons (Feany and Dickson, 1996; Lee et al., 2001). To further
kaline phosphatase demonstrated a unique tau protein isoform in
characterize the GFAP/tau Tg mice, immunostaining was perthe GFAP/tau Tg versus non-Tg mice that comigrated with recomformed on mice from 6 to 24 months of age with antibodies that
binant T34 human tau (Fig. 1D, arrow). Because both GFAP/tau Tg
detect recombinant tau as well as phosphorylation-dependent
lines showed comparable tau expression, the majority of the studies
tau epitopes characteristic of the human diseases (Figs. 3, 4).
to follow, except where indicated, were performed using line 4.
Whereas there was little change in staining pattern of young and
However, both line 4 and line 7 showed comparable results.
old mice with antibodies generated to recombinant tau (Fig. 3A–
C), there was an age-dependent increase in expression of
Human tau expression in astrocytes is associated with altered
phosphorylation-dependent tau epitopes in GFAP/tau Tg mice
GFAP expression
(Figs. 3D–F, 4). These phosphoepitopes epitopes were first deTo analyze the cell-type-specific tau expression in the GFAP/tau
tected in brainstem and spinal cord of ⬃30% of Tg mice by 12
Tg mice, an immunohistochemical analysis was performed on
months of age, and by 18 months, the phosphoepitopes were
6-month-old Tg and control mice using the human-specific
observed in ⬎90% of animals in brainstem, spinal cord, and
monoclonal antibody (MAb) OT12 (Fig. 2). There was robust tau
subcortical nuclei, especially thalamus. By 24 months of age,
expression throughout the brain and spinal cord in the GFAP/tau
there was extensive tau pathology in all animals throughout these
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same regions, as well as cortical pathology
in a subset of animals (Fig. 5). Of note, the
astrocytic tau pathology was often asymmetric in distribution, similar to that described in many of the tauopathies and in
particular CBD (see Fig. 8). And at high
magnification, the astrocytic tau pathology resembled the tufted astrocytes, astrocytic plaques, and thread pathology observed in the human tauopathies (Fig. 3G–
L). Furthermore, the detection of
pathological tau phosphoepitopes coincided with positive Gallyas silver impregnation stains (Figs. 4 F, 5E–H ) (Ikeda et al.,
1994; Takahashi et al., 1996). A subset of
these tau pathologies were both ubiquitin
positive (Fig. 4 E) and stained by thioflavine S, a histochemical dye that binds amyloid fibrils (Fig. 4G–I ). Thus, the GFAP/
tau Tg mice develop an age-dependent
accumulation of tau pathology in astrocytes that histochemically and immunohistochemically resembled that observed
in tauopathies.
Because aggregated pathological tau in
human tauopathies is biochemically insoluble (Lee et al., 2001), we assessed the solubility of the tau in our GFAP/tau Tg mice
by sequential extraction of CNS tissue with
buffers of increasing protein solubilization
strength followed by Western blot analysis
of soluble (Fig. 6 A) and insoluble FAextractable tau proteins (Fig. 6 B–D). Specifically, cortex, brainstem, and spinal
cord extracts were analyzed from pairs of
GFAP/tau Tg and non-Tg mice at 6, 12, 18,
and 24 months of age. Soluble extracts
from the brain and spinal cord showed
only mild and variable changes in tau expression with aging (Fig. 6 A and data not Figure 5. Distribution of tau pathology in GFAP/tau Tg mice. A–H, Immunohistochemical analysis with AT8 (A–D) and Gallyas
silver impregnation stain (E–H ) of CNS regions indicated from 24-month-old GFAP/tau Tg mouse. Robust pathology was obshown). However, there was a progressive served consistently in the spinal cord, brainstem, and thalamus, whereas cortical pathology was highly variable. Scale bars: (in E)
accumulation of insoluble and heavily ag- A–C, E–G, 100 m; (in H ) D, H, 200 m. I, Diagrammatic summary of astrocytic tau pathology shown as coronal sections of the
gregated tau protein in the brainstem and mouse neuroaxis. The density of dots corresponds to frequency and quantity of observed pathology in aged Tg mice. Amyg,
spinal cord of GFAP/tau Tg mice (Fig. 6). Amygdala; Aq, aqueduct; Aud Cx, auditory cortex; Cau/Put, caudate–putamen; CC, corpus callosum; Cereb, cerebellum; DH, dorsal
There was little insoluble tau in cortex, horn; Ent Cx, entorhinal cortex; Hip, hippocampus; Hypo, hypothalamus; LV, lateral ventricle; Mam, mamillary body; Med, meconsistent with the low and variable corti- dulla; Mid, midbrain; Mot Cx, motor cortex; Olf Cx, olfactory cortex; PC, posterior column; Pir Cx, piriform cortex; Sen Cx, sensory
cal tau pathology detected by immunohis- cortex; SN, substantia nigra; Vis Cx, visual cortex; VH, ventral horn; third, third ventricle; fourth, fourth ventricle.
tochemistry. In non-Tg mice, endogenous
determine whether the astrocytic tau pathology in the GFAP/tau Tg
tau protein was not detected in the insoluble fraction of brain and
mice was filamentous, immuno-EM was performed with antibodies
spinal cord (Fig. 6C and data not shown). Furthermore, insoluble
specific for tau phosphoepitopes (Fig. 7). In the thalamus, braintau was abnormally phosphorylated similar to human tauopastem, and spinal cord of 20- to 24-month-old Tg mice, we detected
thies (Fig. 6 D) (Lee et al., 2001). Finally, the insoluble tau protein
accumulations of tau-positive fibrils ranging from 15 to 25 nm in
was detected with human tau-specific antibodies (T14) but not
diameter irregularly arranged in the soma and processes of cells with
antibodies that detect only rodent tau (T49), indicating that the
the morphology of astrocytes (Fig. 7A–D). These filaments were
astrocytic tau pathology is composed exclusively of human tau
composed of either straight fibrils or filaments with a subtle twist;
(Fig. 6 D), which presumably reflects low levels of endogenous
however, AD-like paired helical filaments were not identified. Furtau expression in murine astrocytes (Couchie et al., 1985, 1988).
thermore, the fibrils did not form large bundles as is typical of the
neuronal and oligodendroglial pathology in tauopathies (Komori,
Formation of tau filaments in astrocytes of aged GFAP/tau
1999). In contrast, the coarsely bundled astrocyte-specific intermeTg mice
diate filaments were distinguished easily from the tau filaments and
Ultrastructurally, tau inclusions in astrocytes of human tauopathies
labeled avidly with antibodies to GFAP but were nonreactive with a
exhibit various morphologies ranging from poorly formed fibrils to
straight tubules with a diameter of 15–20 nm (Komori, 1999). To
panel of anti-tau antibodies (Fig. 7E,F).
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(data not shown), in regions with astrocytic tau pathology that colocalized with
phosphorylated tau epitopes (data not
shown). In contrast, there were no changes
in the staining pattern of hsp70 that is associated with the formation of insoluble
tau protein in neurons (Dou et al., 2003)
but not glia (data not shown) (Dabir et al.,
2004). Thus, tau protein expression in astrocytes leads to two distinct stages in the
astrocytic response. Initially, there is an alteration of the intermediate filament network with an increase in immunohistochemically detectable GFAP. This is
followed by the accumulation of phosphotau epitopes, which coincides with the detection of insoluble tau aggregates, a second alteration in the GFAP network and
the induction of low-molecular-weight
heat shock proteins.
Astrocytic tau pathology is associated
with mild disruption of the
blood– brain barrier
Astrocytes now are known to play roles in
Figure 6. Age-dependent accumulation of insoluble, aggregated, and phosphorylated tau protein in GFAP/tau Tg mice. Cortex response to CNS injury, maintenance of
(Cx), brainstem (BS), and spinal cord (SC) from pairs of non-Tg (NTg) and GFAP/tau Tg mice at 6, 12, 18, and 24 months of age were the blood– brain barrier (BBB), immune
sequentially extracted as described in Materials and Methods. A, Immunoblot analysis of 10 g of soluble protein extracted from modulation, and modulation of synaptic
the brainstem of GFAP/tau Tg mice at the age indicated and detected with the human-specific anti-tau MAb T14. There is only mild activity (Ransom et al., 2003). We examand variable change in tau protein expression with increasing age. B, Immunoblot analysis of insoluble tau corresponding to 25 ined the GFAP/tau Tg mice for impairmg of starting wet tissue weight extracted from GFAP/tau Tg mice at the age indicated and detected with the human tau-specific ments in BBB function because we obMAb T14. C, Immunoblot analysis of insoluble tau corresponding to 25 mg of starting wet tissue weight extracted from the spinal served frequent pathology in astrocytic
cord of non-Tg and GFAP/tau Tg mice at the age indicated and detected with polyclonal antibody 17026. Insoluble and heavily end feet that abut endothelial cells to form
aggregated tau is detected in brainstem and spinal cord by 18 months of age. Insoluble tau is not detected in non-Tg mice.
the BBB (Fig. 9). There was evidence of
Arrowheads indicate nonspecific bands that are not recognized by other tau antibodies. D, Immunoblot analysis of insoluble tau
extracted from cortex, brainstem, and spinal cord of 24-month-old GFAP/tau Tg mice and detected with a panel of tau-specific mild BBB disruption by staining brain and
MAb as indicated. In contrast to B and C above, samples corresponding to only 5 mg starting wet tissue weight were loaded on the spinal cord sections from GFAP/tau Tg
gels to reduce the smearing associated with heavily aggregated, insoluble tau protein, which facilitated the visualization of the animals for serum proteins including
predominant tau protein band at ⬃66 kDa. Insoluble tau is phosphorylated at multiple sites (PH1, AT8, and PHF6) and is mouse immunoglobulin and albumin becomposed of human tau only (compare human tau-specific antibody T14 to murine tau-specific antibody T49). The position of fore and after the development of patholmolecular weight markers are depicted on the left. WT, Wild type.
ogy. For example, in non-Tg mice of all
ages and GFAP/tau Tg mice before the deTau pathology induces phenotypic changes in astrocytes
velopment of tau pathology, there was no extravascular immuIn neurodegenerative diseases, tau pathology is associated with
noglobulin or albumin detected. In contrast, in brain regions
reactive changes in affected brain regions including gliosis and
with robust tau pathology, we detected low levels of murine imexpression of specific heat shock proteins (HSPs) such as hsp70 in
munoglobulin (Fig. 9) and albumin (data not shown) in the brain
neurons (Dou et al., 2003) and the low-molecular-weight HSPs
parenchyma, typically associated with cell soma. Although an
hsp27 and ␣B-crystallin in astrocytes and oligodendrocytes
ultrastructural analysis of aged GFAP/tau Tg mice did not reveal
(Dabir et al., 2004). To address specifically the role of the astroovert alterations of the astrocyte foot processes and endothelial
cytic tau pathology in these phenotypic changes, we analyzed the
cell tight junctions (data not shown), these findings suggest the
GFAP/tau Tg mice before and after the development of astrocytic
pathology causes a subtle alteration in astrocyte structure and/or
tau inclusions. As described above, the initial expression of tau in
function that leads to a mild disruption of the BBB. Similar alterastrocytes before the onset of pathological inclusions was associations in the BBB are seen occasionally in the tauopathies, which
ated with an increase in the somatic expression of GFAP (Figs. 2,
over the course of the disease, might contribute to the process of
8). In contrast, the development of pathological tau inclusions
neurodegeneration (Claudio, 1996; Ujiie et al., 2003).
resulted in a redistribution of stainable GFAP in affected astrocytes (Fig. 8). This was associated with a remarkable masking of
Neuron degeneration associated with astrocytic
tau epitopes such as exon 2 (Fig. 8) and the N terminus (data not
tau pathology
shown) that presumably was caused by the altered folding and/or
To assess the impact of the astrocytic tau pathology on neurons
fibrillization of the tau protein (Fig. 8). Furthermore, tauopathies
and their processes, we performed immunohistochemistry on
with prominent glial pathology are associated with the induction
young and aged GFAP/tau Tg and non-Tg mice with panel of
of the low-molecular-weight HSPs such as hsp27 and ␣Bantibodies to phosphorylated neurofilament (NF) epitopes.
crystallin (Dabir et al., 2004). We detected a prominent increase
Phosphorylated NF is normally expressed in axons, and detection
in staining of hsp27 (Fig. 8), and, to a lesser extent, ␣B-crystallin
of these epitopes in neuronal perikarya is indicative of neuronal
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degeneration was associated with neuron loss, neuronal-specific
nuclear protein (NeuN)-positive neurons were quantified in the
spinal cord of aged (20 –24 months of age) Tg and non-Tg mice.
However, there was no statistically significant difference in the
number of NeuN-positive neurons between the two groups (data
not shown).

Discussion

Figure 7. Immuno-EM demonstrates filamentous tau accumulation in astrocytes of aged
GFAP/tau Tg mice. A, Immuno-EM of filamentous inclusion in spinal cord gray matter of a
22-month-old GFAP/tau Tg mouse labeled with AT8. B, High-power photomicrograph of the
boxed area in A showing tau-positive filaments. C, D, High-power photomicrographs of the
tau-positive filaments depicted by the arrowhead (C) and the arrow (D) in B. Arrowheads in C
and D indicate filaments that are immunolabeled with the AT8. E, Immuno-EM of GFAP-positive
filaments in astrocytes of spinal cord from same mouse depicted in A–D. F, High-power photomicrograph of the boxed area in E showing coarsely bundled GFAP-positive intermediate
filaments. Scale bar: (in F ) A, 1.25 mm; B, E, 500 nm; C, D, F, 100 nm.

injury (Julien and Mushynski, 1998). In aged non-Tg mice, all
antibodies to phosphorylated NFs stained axons, whereas the cell
bodies were nonreactive (Fig. 10). In contrast, in regions with
abundant astrocytic tau pathology, there were frequent neurons
that were stained with multiple antibodies to these phosphorylated NF epitopes, thereby indicating neuronal injury, features
similar to that observed in ballooned neurons characteristic of a
variety of neurodegenerative diseases including CBD (Dickson et
al., 1986). To further characterize the changes in neurons, we
performed transmission EM on Tg and non-Tg mice. In aged
GFAP/tau Tg mice (⬎20 months of age), we observed frequent
axonal degeneration with disruption of the associated myelin
(Fig. 10). Occasional axons showed well circumscribed inclusions
composed of amorphous granular material that on immuno-EM
were negative for antibodies to tau (Fig. 10 H). In addition, there
were numerous degenerative foci with myelin breakdown, macrophage infiltration, and electron-dense bodies. These changes
were not observed in Tg mice ⬍12 months of age or in agematched non-Tg animals. To determine whether the neuronal

The defining feature of tauopathies is filamentous tau inclusions
in neurons and glia. It is mostly accepted that neuronal tau inclusions play a pathogenic role in neurodegeneration, especially in
view of data from animal models of neuronal tau pathology in
species ranging from C. elegans to mouse (Götz et al., 2004).
However, the contribution of the glial tau pathology, particularly
that in astrocytes, to brain degeneration remains a mystery. In
fact, it is still debated whether the glial tau pathology is a reactive
or a degenerative process (Ikeda et al., 1995; Komori, 1999).
However, it was demonstrated recently that the astrogliosis observed in PSP was associated with neurofibrillary tangle formation and not astrocytic tau pathology (Togo and Dickson, 2002),
and preliminary evidence implicates the astrocytic pathology in
tauopathies with glutamate excitotoxicity and oxidative stress
(Komori et al., 1998; Komori, 1999). To address specifically the
role of the astrocytic tau pathology in pathogenesis of neurodegeneration in tauopathies, we sought to model this astrocytic
pathology in mice, and we report data from this model implicating astrocytic tau pathology in brain generation.
There are few reports of model systems enabling investigation
of the role of tau pathology in glia. In 2001, Götz et al. described
tau inclusions in oligodendrocytes as well as neurons in Tg mice
expressing the G272 V FTDP-17 mutation in an inducible system
using the prion protein promoter. The oligodendrocytic inclusions were reported as thioflavine S positive, immunoreactive
with antibodies to phosphorylated tau protein, and ultrastructurally, composed of tubulofilamentous aggregates that were 17–20
nm in diameter with a periodicity of 75 nm. However, in contrast
to authentic tauopathies, the inclusions were not Gallyas silver
positive, tau showed only a limited shift to insoluble species, and
there were no functional consequences of these tau pathologies.
More recently, Higuchi and colleagues described tau pathology in
oligodendrocytes, and to a lesser extent, in astrocytes, in aged Tg
mice using a tau minigene construct combined with the murine
T␣1 tubulin promoter leading to expression of tau isoforms with
three microtubule-binding repeats (Higuchi et al., 2002a). Aged
mice accumulated thioflavine S- and Gallyas-positive filamentous aggregates in oligodendrocytes and, to a lesser extent, astrocytes, in association with the accumulation of insoluble tau protein. Furthermore, the pathology was associated with glial cell
degeneration and motor deficits, providing the first direct evidence linking glial pathology to neurodegeneration. However,
the relative contribution of the tau pathology in oligodendrocytes
versus astrocytes to the observed phenotype was difficult to determine, especially because neuronal tau abnormalities also occurred in this model. Finally, tau inclusions were reported to
occur in oligodendrocytes and astrocytes of Tg mice expressing
four microtubule-binding repeat tau isoforms with the P301 L
mutation driven by the prion protein promoter in association
with amyotrophy and progressive motor dysfunction (Lin et al.,
2003). But, as in the other models systems described above, it was
difficult to dissect out the independent contributions of glial tau
pathologies to the observed phenotype.
Recent in vitro studies have contributed to understanding the
biological consequences of tau abnormalities in astrocytes by us-
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neurodegenerative disease. First, we
showed that there is somatic expression of
the human tau protein in young Tg mice,
which initially is not detected with antibodies to phosphorylated tau epitopes,
and this early stage is characterized by stable tau expression associated with a redistribution of GFAP resembling reactive astrocytes at this early age (Pekny and Pekna,
2004). Although tau expression in astrocytes is normally low, the specific mechanism leading to the altered tau expression
in the disease state is unknown, and tau
pathology in astrocytes is not typical of all
tauopathies such as AD with extensive
neuronal tau pathology (Lee et al., 2001).
Thus, the alteration in tau expression most
likely reflects a disease-specific alteration
in tau protein metabolism.
The GFAP/tau Tg mice develop an agedependent accumulation of tau pathology
restricted to astrocytes that morphologically, histochemically, and biochemically
bears verisimilitude to the astrocytic tau
pathology characteristic of a subset of
tauopathies such as PSP, CBD, PiD, and
the autosomal dominant disorder FTDP17. This second stage of tau pathology is
characterized by the emergence of
phospho-tau epitopes that coincides with
their detection by Gallyas silver stains and
the accumulation of insoluble, FAextractable tau protein. A subset of the tau
pathology in the GFAP/tau Tg mice also is
detected with antibodies to ubiquitin and,
similar to human tauopathies, there is induction of low-molecular-weight HSPs in
regions with robust pathology (Dabir et
al., 2004). Ultrastructurally, the astrocytic
inclusions in the GFAP/tau Tg mice are
Figure 8. Phenotypic changes associated with tau pathology in astrocytes. A–I, Two-color immunofluorescence staining of composed of tau filaments with a diameter
spinal cord from 24-month-old GFAP/tau Tg mice. OT12, which is specific for exon 2 of human tau, colocalizes with GFAP (G–I ). In of 15–25 nm. Although some of the tau
contrast, in regions with AT8-positive tau pathology in astrocytes, there is a relative reduction of stainable GFAP (A–F ). J, K, inclusions in these mice resemble the asImmunohistochemistry for hsp27, from the thalamus of 24-month-old GFAP/tau Tg and non-Tg (NTg) mice. Tau pathology (J, trocytic plaques and tufted astrocytes typinset) is associated with increased staining of hsp27. Scale bars: (in A) A–C, G–I, 400 m; (in D) D–F, 100 m; (in K ) J, K, 200 mm. ical of CBD and PSP, respectively (Feany
and Dickson, 1996; Komori, 1999), the
ing adenoviral-mediated gene transfer to overexpress the longest
majority of the pathology was similar to the thread pathology charhuman tau isoform in primary rat astrocytes that led to decreases
acteristic of CBD (Dickson et al., 2001). In addition, similar to CBD,
in stable, detyrosinated microtubules and the accumulation of
the pathology often showed an asymmetric distribution that is not
destabilized (acetylated and tyrosinated) tubulin (Yoshiyama et
described in other tau Tg model systems (Götz et al., 2004), suggestal., 2003). Because these changes also were associated with a dising the possibility that astrocytic pathology contributes to the asymruption of the intermediated filaments, kinesin-dependent ormetric pattern of pathology observed in some of the human tauopaganelle trafficking, and Golgi fragmentation culminating in nonthies. The astrocytic tau pathology is most prominent in subcortical
apoptotic cell death, it is plausible that tau accumulation in
nuclei, brainstem, deep cerebellar nuclei, and spinal cord, particuastrocytes disrupts microtubule stability. Similarly, in the GFAP/
larly within the gray matter similar to that observed in the tauopathy
tau Tg mice, the expression of tau in astrocytes leads to a redisPSP. However, this topographic distribution of tau pathology most
tribution of the intermediate filament GFAP. However, no filalikely reflects the regional variation in tau expression driven by the
mentous tau inclusions occurred in the in vitro model system,
GFAP promoter in the pGfa2 vector (Brenner et al., 1994), and aland the effects of tau overexpression on the function of astrocytes
though robust spinal cord pathology is not typical of tauopathies, tau
were not assessed.
inclusions do occur in the spinal cord of patients with PSP, CBD, and
Thus, by developing tau pathologies exclusively in astrocytes,
amyotropic lateral sclerosis/parkinsonism dementia complex of
the GFAP/tau Tg mice described herein provide unique insights
Guam (Mori et al., 1994; Oyanagi et al., 1997; Schmidt et al., 2000;
into the role of astrocytic tau abnormalities in mechanisms of
Vitaliani et al., 2002).
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However, experiments to assess behavioral abnormalities are currently underway, and preliminary evidence indicates impaired
motor function in GFAP/tau Tg mice in comparison to non-Tg
age-matched controls (data not shown). Longitudinal studies on
a large cohort of animals are currently underway to further characterize these motor deficits and determine the relationship between the behavioral phenotype and tau expression in astrocytes
versus the development of bona fide astrocytic tau pathology.
Although the specific mechanism underlying the neurodegenerative changes is unknown, it might reflect the toxic effects of the
tau aggregates as proposed in Alexander’s disease, which is caused
by mutations in the GFAP gene leading to filamentous inclusions
composed of GFAP in astrocytes (Head et al., 1993; Brenner et al.,
2001; Johnson and Brenner, 2003; Mignot et al., 2004). Notably,
these astrocytic GFAP aggregates have been proposed to lead to
neurodegeneration by a variety of mechanisms including myelin
destruction, excitotoxicity, oxidative stress, and disruption of the
BBB (Mignot et al., 2004).
In summary, the GFAP/tau Tg mice provide the first model of
tau pathology exclusively in astrocytes. As such, these Tg mice
will be useful in delineating the role of astrocytic pathology in the
pathogenesis of neurodegeneration in a variety of tauopathies
including PSP, CBD, PiD, and FTDP-17.
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